Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 12/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.45 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4594005 | 0.89 | MAPK1 (0.47) | MKNK1MKNK2 | |
| SCHEMBL3801039 | 0.87 | MKNK1 (0.45) | MKNK1PIK3CD | |
| SCHEMBL3803006 | 0.84 | PIK3CD (0.46) | MKNK1PIK3CD | |
| SCHEMBL2409827 | 0.83 | MKNK2 (0.62) | MKNK1MKNK2 | |
| SCHEMBL2409831 | 0.83 | MKNK2 (0.62) | MKNK1MKNK2 | |
| SCHEMBL12279895 | 0.83 | MKNK2 (0.62) | MKNK1MKNK2 | |
| SCHEMBL12318598 | 0.82 | MKNK2 (0.67) | MKNK1MKNK2 | |
| SCHEMBL2407058 | 0.82 | MKNK2 (0.60) | MKNK1MKNK2 | |
| SCHEMBL2410208 | 0.82 | MKNK2 (0.60) | MKNK1MKNK2 | |
| SCHEMBL2409877 | 0.82 | MKNK2 (0.67) | MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100143341-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2010-06-10 | — | — | US | claimed |
| EP-1899353-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DeveloGen Aktiengesellschaft (DE) | 2008-03-19 | — | — | EP | claimed |
| WO-2007059905-A9 | THIENOPYRIMIDINES TREATING INFLAMMATORY DISEASES | DEVELOGEN AG (DE) | 2007-11-01 | — | — | WO | claimed |
| WO-2007059905-A2 | THIENOPYRIMIDINES TREATING INFLAMMATORY DISEASES | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2007-05-31 | — | — | WO | claimed |
| WO-2006136402-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | WO | claimed |
| US-20100247517-A1 | USE OF MNK INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Boehringer Ingelheim Internationational GmbH (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100143341-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2010-06-10 | — | — | US | disclosed |
| EP-1899353-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DeveloGen Aktiengesellschaft (DE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007059905-A9 | THIENOPYRIMIDINES TREATING INFLAMMATORY DISEASES | DEVELOGEN AG (DE) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007059905-A2 | THIENOPYRIMIDINES TREATING INFLAMMATORY DISEASES | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2007-05-31 | — | — | WO | disclosed |
| WO-2006136402-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100247517-A1 | USE OF MNK INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | NEK9, TTBK1, NEK2 | MKNK1 14/4885PIK3CD 1614/4885MKNK2 11/4885 |
| US-20100143341-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DTYMK, CMPK1, PDXK | MKNK1 74/4885PIK3CD 378/4885MKNK2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.